Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Reply to comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial.

Bhalla AK, Bhalla AS, Coates LC, Packham JC, Creamer P, Hailwood S, Chakravarty K, Mulherin D, Taylor G, Mattey DL.

Clin Exp Rheumatol. 2017 Apr 18. [Epub ahead of print]

PMID:
28421992
2.

Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial.

Coates L, Packham JC, Creamer P, Hailwood S, Bhalla AS, Chakravarty K, Mulherin D, Taylor G, Mattey DL, Bhalla AK.

Clin Exp Rheumatol. 2017 Jan 4. [Epub ahead of print]

PMID:
28079501
3.

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators..

Arthritis Rheumatol. 2015 May;67(8):2011-9. doi: 10.1002/art.39169. Erratum in: Arthritis Rheumatol. 2015 Nov;67(11):3096.

4.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
5.

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate.; Wellcome Trust Case Control Consortium., Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J.

Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11.

6.

Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis.

Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, Taylor GJ, Bhalla AK.

Arthritis Res Ther. 2012 May 28;14(3):R127. doi: 10.1186/ar3857.

7.

Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.

Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)..

J Rheumatol. 2012 May;39(5):929-32. doi: 10.3899/jrheum.111315. Epub 2012 Apr 1.

PMID:
22467927
8.

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate., Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.

PMID:
19926672
9.

Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone.

Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH; PRISM Trial Group..

J Bone Miner Res. 2010 Jan;25(1):20-31. doi: 10.1359/jbmr.090709.

10.

Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.

Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A; BRAGGSS..

Pharmacogenet Genomics. 2009 Apr;19(4):319-23. doi: 10.1097/FPC.0b013e328328d51f.

PMID:
19262425
11.

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.

Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A; BRAGGSS..

Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ard.2007.084715. Epub 2008 Mar 28. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

12.

Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.

Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T.

Rheumatology (Oxford). 2005 Jun;44(6):813-8. Epub 2005 Feb 3.

PMID:
15695300
13.

Granulomatous vasculitis: an unusual renal vasculitis.

Hailwood SJ, Scott DG, Barker TH, Heaton A.

Nephrol Dial Transplant. 1999 Apr;14(4):952-3. No abstract available.

PMID:
10328477
14.

The use of granulocyte colony-stimulating factor in joint replacement surgery in a patient with Felty's syndrome.

Hailwood SJ, Harley LJ, Merry P.

Br J Rheumatol. 1997 Nov;36(11):1232-3. No abstract available.

PMID:
9402873

Supplemental Content

Loading ...
Support Center